COVID-19 vaccine quandary for international students universityworldnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from universityworldnews.com Daily Mail and Mail on Sunday newspapers.
comments
Assuming that the paperwork all goes as planned, the United States will likely have three novel coronavirus vaccines available by late spring: the Moderna vaccine, the Pfizer vaccine, and the forthcoming Oxford University/AstraZeneca vaccine, which is already being distributed in the United Kingdom and will soon face regulatory scrutiny here.
Many Americans don t have a choice as to which vaccine they get: their health care provider issues whatever they have on hand. Yet as time goes on and scarcity diminishes, some of us might actually be faced with a choice. That raises a curious question: With so many vaccines available to the public, which one should patients opt for if they do have the choice?
What do we know about the SARS-CoV-2 vaccines so far?
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to an unparalleled focus on developing preventive and therapeutic measures. Within a year of the pandemic’s onset, the world saw the approval of the first COVID-19 vaccines for emergency use. Scores more are being developed or are in late-phase clinical trials. A new paper published in the journal
Advanced Drug Delivery Reviews sums up what is known about these vaccines so far.
Many national and international research collaborations and drives have also come up as a result of the urgent need for vaccines to arrest or at least contain the spread of the virus. These are aimed at funding and coordinating various phases of vaccine development, as well as codifying and streamlining manufacturing processes and global distribution of the final vaccine. The money and efforts that ha